Asthma
|
In a double-blind, placebo-controlled clinical study, 80 patients with chronic asthma were treated with 900 mg/day of Boswellia gum resin or placebo for 6 weeks. Only 27% of patients in the control group showed improvement, whereas 70% of patients taking Boswellia improved. After taking Boswellia, improvements were observed for shortness of breath, number of attacks, and respiratory capacity as well as indicators of inflammation.
Comparing the Boswellia group to the placebo group, there was a significant improvement in FEV1, a measure of bronchial obstruction (p=0,0001). PEFR, a measure of lung capacity was also significantly increased (p=0.0001). The number of attacks was lower in the Boswellia group (p=0.0001). |
|
Additionally, Boswellia showed substantial (p<0.05) improvements compared to placebo in secondary outcome parameters such as rhonchi, eosinophil count, ESR, and respiratory rate. Two patients who received Boswellia complained of epigastric pain and nausea.
It should not be assumed that the inhibition of leukotrienes is the only mechanism by which Boswellia
provides beneficial effects for asthma, especially when the anti-allergic activity from experimental models.
Journal of the American Herbalist Guild Vol 6 issue 1
It should not be assumed that the inhibition of leukotrienes is the only mechanism by which Boswellia
provides beneficial effects for asthma, especially when the anti-allergic activity from experimental models.
Journal of the American Herbalist Guild Vol 6 issue 1